Please login to the form below

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Endocyte adding .

Novartis culls pipeline to focus on most transformative science

$8.7bn, and cancer specialist Endocyte for $2.1bn.
Novartis buys cancer specialist Endocyte for $2.1bn

Heading up Endocyte’s pipeline is. 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). ... Novartis said radiopharma is a “key growth driver”for its business and that
Merck's vintafolide fails ovarian cancer trial

Merck's vintafolide fails ovarian cancer trial. Major blow for drug’ s original developers Endocyte. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last 12 months.
EMA backs Janssen rare disease drug for approval

it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs
Boehringer/Lilly's empagliflozin among CHMP recommendations

There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

Endocyte appoints Parexel's Scot Harper to oversee clinical trials. He also previously served at Novartis and Lilly. ... In addition, Endocyte says it has three new drug candidates scheduled to enter the clinic before the end of 2014.
Endocyte brings in senior figures from BMS and Amgen

Endocyte brings in senior figures from BMS and Amgen. Appoints Torsten Hoof and Ulf Staginnus as company prepares to launch cancer drugs. ... The two additions follow the hire in July 2012 of Endocyte's first chief commercial officer, David Meek from

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Account Director development role to Business Director, H...: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...